TRCT
VBIO

Tower Research Capital (TRC)’s Valion Bio VBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$517 Sell
584
-1,064
-65% -$1.09K ﹤0.01% 4851
2025
Q4 		$2.39K Buy
+1,648
New +$3.76K ﹤0.01% 4541
2025
Q1 		– Sell
-1,111
Closed -$6.53K – 5781
2024
Q4 		$6.53K Buy
1,111
+31
+3% +$144 ﹤0.01% 4162
2024
Q3 		$4.59K Buy
1,080
+651
+152% +$3.93K ﹤0.01% 4487
2024
Q2 		$2.84K Buy
429
+67
+19% +$843 ﹤0.01% 4960
2024
Q1 		$7.7K Buy
362
+223
+160% +$5.15K ﹤0.01% 4162
2023
Q4 		$4.24K Buy
139
+103
+286% +$2.96K ﹤0.01% 4978
2023
Q3 		$1.06K Buy
36
+29
+414% +$2.14K ﹤0.01% 5414
2023
Q2 		$1.17K Hold
7
– – ﹤0.01% 5443
2023
Q1 		$2K Hold
7
– – ﹤0.01% 5404
2022
Q4 		$7K Buy
7
+2
+40% +$4.49K ﹤0.01% 4623
2022
Q3 		$11K Buy
5
+2
+67% +$6.76K ﹤0.01% 4467
2022
Q2 		$10K Buy
3
+1
+50% +$2.93K ﹤0.01% 4486
2022
Q1 		$5K Buy
+2
New +$6.54K ﹤0.01% 5102

Other funds holding VBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Tower Research Capital (TRC)'s VBIO Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Valion Bio (VBIO) stake by 65% in Q1 2026, selling an estimated $1.09K and leaving 584 shares worth $517. The position accounts for ﹤0.01% of the portfolio, ranked #4851.

Tower Research Capital (TRC) first reported a position in VBIO in Q1 2022 and has held it in 14 quarters since. The position peaked at $11K in Q3 2022. 9 funds tracked by Wall St. Rank hold VBIO as of Q1 2026.

  • Tower Research Capital (TRC) held 584 shares of Valion Bio worth $517 as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,064 Valion Bio shares in Q1 2026, an estimated $1.09K.
  • Valion Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4851 holding.
  • Tower Research Capital (TRC) first reported a position in Valion Bio in Q1 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Valion Bio position peaked at $11K in Q3 2022.
  • 9 funds tracked by Wall St. Rank held Valion Bio as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.